BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 15, 2026
Breaking News: Best of BioWorld Science: Q1Breaking News: Best of BioWorld: Q1Breaking News: Best of BioWorld: Q1
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

AI-generated image for cancer cells observed under a microscope
Cancer

Moma’s WRN inhibitor causes preclinical tumor regression

Aug. 29, 2025
No Comments
Moma Therapeutics Inc. has released data regarding their Werner syndrome helicase (WRN) inhibitor MOMA-341 for the potential treatment of cancer. MOMA-341 is a potent and selective WRN inhibitor, the action of which is through covalent ligation.
Read More
Illustration of double helix
Cancer

TYRA-200: a potent oral FGFR inhibitor tackling resistance mutations

Aug. 29, 2025
No Comments
Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations.
Read More
White blood cells with red blood cells
Hematologic

Vanda’s VGT-1849B designated orphan drug for polycythemia vera

Aug. 29, 2025
No Comments
The FDA has granted orphan drug designation to Vanda Pharmaceuticals Inc.’s VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV).
Read More
Scientists shaking hands in the lab
Endocrine/metabolic

Novo Nordisk and Replicate enter cardiometabolic collaboration

Aug. 29, 2025
No Comments
Replicate Bioscience Inc. and Novo Nordisk A/S have entered into a multiyear research collaboration that will leverage Replicate’s novel self-replicating RNA (srRNA) platform to develop new therapeutic candidates to treat obesity, type 2 diabetes and other cardiometabolic diseases.
Read More
Cancer cell targeted in crosshairs
Immuno-oncology

Tidewave Bio gains FDA feedback on TBC-1 for solid tumors

Aug. 29, 2025
No Comments
Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal, off-the-shelf immunotherapy platform that is converted into a patient-specific precision medicine in real time using a tumor biopsy.
Read More
Pill over molecule structures
Neurology/psychiatric

Palobiofarma A2A/H3 receptor antagonist project yields candidate

Aug. 29, 2025
No Comments
Palobiofarma SL has announced the successful completion of an industrial research project investigating dual antagonist compounds targeting adenosine A2A and histamine H3 receptors for the treatment of Parkinson’s disease.
Read More
Endocrine/metabolic

Pan-EphB inhibitor STA-013 improves metabolic syndrome

Aug. 29, 2025
No Comments
The signaling of ephrin B (EphB) has been shown to be involved in the progression of metabolic disorders, among others. In this context, researchers from Texas Tech University Health Sciences Center have developed a pan-EphB inhibitor – STA-013 – for the treatment of metabolic syndrome.
Read More
Illustration of damaged brain, neurons
Cancer

Neuronal damage promotes tumor proliferation and drug resistance

Aug. 29, 2025
By Mar de Miguel
No Comments
Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance.
Read More
Vibrant DNA double helix
Immune

Research uncovers gene variant role in disease biology

Aug. 28, 2025
By Nuala Moran
No Comments
New research has filled in missing links between gene variants that have been implicated in disease through genome-wide association studies and how the variants drive disease pathology. The research involved using induced pluripotent stem cells derived from healthy donors and transforming them into macrophages. These were then exposed to 24 different stimuli mimicking infection and inflammation, and the gene expression profiles assessed six and 24 hours later, to see which genes were turned on or off in response.
Read More
Neurology/psychiatric

Chengdu Kanghong Pharmaceutical discovers new OX2 receptor antagonists

Aug. 28, 2025
Chengdu Kanghong Pharmaceutical Co. Ltd. has described orexin OX2 receptor (OX2R; HCRTR2) antagonists reported to be useful for the treatment of secondary insomnia and major depression.
Read More
Previous 1 2 … 210 211 212 213 214 215 216 217 218 … 18041 18042 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing